Development of Alpha-1 Antitrypsin Gene Therapeutic as Treatment for COPD

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL082384-01
Agency Tracking Number: HL082384
Amount: $97,589.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Solicitation Year: 2005
Award Year: 2005
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Generx+, Inc., C/O Emtech Bio, Atlanta, GA, 30306
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (404) 712-9355
Business Contact
Phone: (404) 712-9355
Research Institution
DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the U.S. and is associated with an imbalance in proteolytic activity in the lungs. Treatment is largely aimed at symptom remediation using bronchodilators and corticosteroids, but these do not treat the underlying disease process. We are developing a gene-based therapy to treat COPD that supplements levels of alpha-1 antitrypsin (a potent anti-proteolytic protein) in at risk regions of the lungs. The studies proposed in the specific aims listed below will specifically test the anti- proteolytic potency, anti-inflammatory effects, and efficacy in preventing or reversing emphysema by expression of the AAT gene in mice. Specific Aims: 1. Determine time course of AAT gene expression in C57BL/6 mice following intratracheal instillation and intravenous injection of the human AAT gene formulated in a plasmid and combined with a monovalent cationic liposome. 2. Establish models of emphysema in other groups of mice through intranasal instillation of porcine pancreatic elastase. 3. Examine effects of AAT gene delivery on attenuation of emphysema in mice. Specifically, to determine whether or not emphysema development in mice can be avoided, attenuated, and/or reversed we will deliver the AAT gene as a lipoplex: 1) weekly prior to the initial dose of elastase; 2) in a single dose simultaneous with the initial dose of elastase; 3) weekly starting at approximately two weeks after elastase delivery (when emphysema is fully established); and 4) weekly during the two weeks prior to fully established emphysema.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government